Abstract
Friedreich's ataxia (FRDA) is an inherited, progressive neurodegenerative disease that typically affects teenagers and young adults. Therapeutic strategies and disease insight have expanded rapidly over recent years, leading to hope for the FRDA population. There is currently no US FDA-approved treatment for FRDA, but advances in research of its pathogenesis have led to clinical trials of potential treatments. This article reviews emerging therapies and discusses future perspectives, including the need for more precise measures for detecting changes in neurologic symptoms as well as a disease-modifying agent.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1 . Parkinsonism & related disorders. Ataxias. Pakinsonism Relat. Disord. 13, S391–S394 (2007).
- 2 Unique origin and specific ethnic distribution of the Friedreich ataxia GAA expansion. Neurology 54, 2322–2324 (2000).
- 3 The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am. J. Hum. Genet. 59, 554–560 (1996).
- 4 . Cerebellar ataxias. Curr. Opin. Neurol. 22, 419–429 (2009).
- 5 Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335, 1169–1175 (1996).
- 6 Ataxia rating scales – psychometric profiles, natural history and their application in clinical trials. Cerebellum 11, 488–504 (2012). •• This is a comprehensive review of ataxia rating scales where the scales are systematically reviewed and critiqued.
- 7 Bilogical and clinical characteristics of the European Friedreich's ataxia consortium for translational studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 14(2), 174–182 (2015).
- 8 Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies. Mov. Disord. 24(7), 984–992 (2009).
- 9 International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J. Neurol. Sci. 145, 205–211 (1997).
- 10 . Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales. J. Neurochem. 126(Suppl. 1), 118–124 (2013).
- 11 Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64, 1261–1262 (2005).
- 12 . Idebenone: a review of its pharmacodynamics and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders. Drugs Aging 5, 133–152 (1994).
- 13 Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month Phase III study (IONIA). Am. Heart J. 161, 639–645 (2011).
- 14 . A phase 3 double-blind, placebo-controlled trial of idebenone in Friedreich ataxia. Arch. Neurol. 67(8), 941–947 (2010).
- 15 Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart. 87, 346–349 (2002).
- 16 . Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60(10), 1676–1679 (2003).
- 17 Idebenone treatment in pediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur. J. Paediatr. Neurol. 12, 470–475 (2008).
- 18 . Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 6, 878–886 (2007).
- 19 Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with ataxia. Ann. Neurol. 49(5), 590–596 (2001).
- 20 Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 62(4), 621–626 (2005).
- 21 . Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficiency of vitamin E and coenzyme Q10 therapy. Eur. J. Neurol. 15(12), 1371–1379 (2008).
- 22 A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial. Mov. Disord. 27(8), 1026–1033 (2012).
- 23 Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS ONE 8(2), e55910 (2013).
- 24 An open-label trial in Friedreich ataxia suggest clinical benefit with high-dose resveratrol, without effect on frataxin levels. J. Neurol. 262(5), 1344–1353 (2015).
- 25 L-Carnitine and creatine in Friedreich's ataxia, A randomized, placebo-controlled crossover trial. J. Neural. Transm. 112, 789–796 (2005).
- 26 . Action of actylcarnitine on age-dependent modifications of mitochondrial membrane proteins from rat cerebellum. Neurochem. Res. 13(10), 909–916 (1988).
- 27 . Double-blind, crossover, placebo-controlled clinical trial with L-acetylcarnitine in patients with degenerative cerebellar ataxia. Clin. Neuropharmacol. 23(2), 114–118 (2000).
- 28 . Field testing of an ataxia scoring and staging system. Can. J. Neurol. Sci. 7, 339–344 (1980).
- 29 . The rebound phenomenon of Gordon Holmes. Arch. Neurol. 34(4), 250 (1977).
- 30 Targeting lipid peroxidation and mitochondrial I mbalance in Friedreich's ataxia. Pharmacol. Res. 99, 344–350 (2015).
- 31 Small amounts of isotopereinforced polyunsaturated fatty acids suppress lipid autoxidation. Free Radic. Biol. Med. 53(4), 893–906 (2012).
- 32 Unusual kinetic isotope effects of deuterium reinforced polyunsaturated clinical features fatty acids in tocopherol-mediated free radical chain oxidations. J. Am. Chem. Soc. 136(3), 838–41 (2014).
- 33 . Deferiprone for the treatment of Friedreich's ataxia. J. Neurochem. 126(1), 142–146 (2013).
- 34 Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. Ann. Neurol. 76(4), 509–521 (2014).
- 35 Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum 10(1), 1–8 (2011).
- 36 Study of beta cells and neurons indicate incretin analogs as potential therapeutics for Friedreich's ataxia. Neurology 84(14), Suppl. S32.005 (2015).
- 37 Unveiling a common mechanism of apoptosis in β-cells and neurons in Friedreich's ataxia. Hum. Mol. Genet. 24(8), 2274–2286 (2015).
- 38 Central role and mechanism of β-cell dysfunction and death in Friedreich ataxia-associated diabetes. Ann. Neurol. 72(6), 971–982 (2012).
- 39 PPAR-γ agonist azelaoyl PAF Increases frataxin protein and mRNA expression. New implications for the Friedreich ataxia therapy. Cerebellum 8, 98–103 (2009).
- 40 Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS ONE 4, 4253–4264 (2009).
- 41 Recombinant human erythropoietin: effects on frataxin expression in vitro. Eur. J. Clin. Invest. 35(11), 711–717 (2005).
- 42 . Friedreich ataxia: clinical pilot trial with recombinant human erythropoietin. Ann. Neurol. 62(5), 521–524 (2007).
- 43 Safety and tolerability of carbamylated erythropoietin in Friedreich ataxia. Mov. Disord. 29(7), 935–939 (2014).
- 44 Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial. Mov. Disord. 3(27), 446–449 (2012).
- 45 Preventing the ubiquitin-proteasome-dependent degradation of frataxin, the protein defective in Friedreich's ataxia. Hum. Mol. Genet. 20(7), 1253–1261 (2011).
- 46 . IGF-1 in Friedreich's ataxia – proof-of-concept trial. Cerebellum Ataxias. 1(10),
doi:10.1186/2053-8871-1-10 (2014). - 47 . Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich ataxia. J. Neurochem. 126(10), 147–154 (2013).
- 48 . Expended GAA repeats impair FXN gene expression and reposition the FXN locus to the nuclear lamina in single cells. Hum. Mol. Genet. 24(12), 3457–3471 (2015).
- 49 Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich ataxia: an exploratory, open-label, dose escalation study. Lancet 384, 504–513 (2014).
- 50 Histine deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol. 2(10), 551–558 (2006).
- 51 . Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich ataxia. J. Neurochem. 126(1), 147–154 (2013). •• An in-depth review of HDAC inhibitors, their effectiveness and the prospect of future clinical studies.
- 52 HDAC inhibitors correct frataxin deficiency in a Friedreich mouse model. PLoS ONE 3(4), e1958 (2008).
- 53 SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology 71, 486–492 (2008).
- 54 Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model. Hum. Mol. Genet. 21, 2855–2861 (2012). • Provides detailed information on Interferon gamma and its potential as an effective treatment of Friedreich's ataxia.
- 55 Open-label pilot study of interferon gamma-1b in Friedreich ataxia. Acta Neurol. Scand. 132(1), 7–15 (2015).
- 56 Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia – open-label trial. Acta. Neurol. Scand. 129, 32–40 (2014).
- 57 Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich's ataxia: an open-label trial. Cerebellum 12, 713–720 (2013).
- 58 . Physostigmine for Alzheimer's disease. Cochrane Databse Syst. Rev. 2, CD001499 (2001).
- 59 Double-blind crossover study with physostigimine in patients with degenerative cerebellar disease. Arch. Neurol. 54(4), 397–400 (1997).
- 60 . Action of physostigmine on inherited ataxia. Adv. Neurol. 21, 195–204 (1978).
- 61 . Double-blind, triple-crossover trial of low doses of oral physostigmine in inherited ataxias. Neurology 31, 288–292 (1981).
- 62 Riluzole in cerebellar ataxia. Neurology 74, 839–845 (2010).
- 63 Riluzole in patients with hereditary cerebellar ataxia: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 14, 985–991 (2015).
- 64 . Selective regulation of spontaneous activity of neurons if the deep cerebellar nuclei by N-type calcium channels in juvenile rats. J. Physiol. 10, 2523–2538 (2008).
- 65 . The role of SK calcium-dependent potassium currents on regulating the activity of deep cerebellar nucleus neurons: a dynamic clamp study. Cerebellum 7(4), 542–543 (2008).
- 66 . Modulation of recombinant and native neuronal SK channels by the neuroprotective drug riluzole. Eur. J. Pharmacol. 449, 47–54 (2002).
- 67 A randomized trail varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 78(8), 545–550 (2012).
- 68 Clinical Trials Database. Identifier: NCT00803868. https://clinicaltrials.gov/ct2/show/NCT00803868.
- 69 . The treatment of Friedeich's ataxia with amantadine. Neurology 38, 1478–1480 (1988).
- 70 A double-blind cross-over trial of amantadine hydrochloride in Friedreich's ataxia. Can. J. Neurol. Sci. 20, 52–55 (1993).
- 71 . Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 73, 1823–1830 (2009).
- 72 . Long-term effects of coordinative training in degenerative cerebellar disease. Movm. Disord. 25, 2239–2246 (2010).
- 73 . Motor training in degenerative spinocerebellar disease: Ataxia-specific improvements by intensive physiotherapy and exergames. Biomed. Res. Int.
doi:10.1155/2014/583507 (2014). - 74 Video game-based coordinative training improves ataxia in children with degenerative ataxia. Neurology 79(20), 2056–2060 (2012).
- 75 Videogame-based coordinative training can improve advanced, multisystemic early-onset ataxia. J. Neurol. 260(10), 2656–2658 (2013).
- 76 Prevention and reversal of severe mitochondiral cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia. Nat. Med. 20, 542–547 (2014). •• Provides information on promising research in gene therapy for treating cardiomyopathy in the Friedreich's ataxia population.
- 77 Excision of expanded GAA repeats alleviates the molecular phenotype of Friedreich's ataxia. Mol. Ther. 23(6), 1055–1065 (2015).
- 78 R-loops associated with triplet repeat expansion promote gene silencing in Friedreich ataxia and fragile X syndrome. PLOS Genetics 10(5), 1–13 (2014).
- 79 Frataxin-bypassin Isu1: characterization of the bypass activity in cells and mitochondria. Biochem. J. 459(1), 71–81 (2014).
- 80 Idebenone treatment in Friedreich ataxia: neurological, cardiac and biochemical monitoring. Neurology 60(10), 1679–1681 (2003).
- 81 Effect of idebenone on cardiomyopathy in Friedreich ataxia: a preliminary study. Lancet 354(9177), 477–479 (1999).
- 82 Antioxidant treatment of patients with Friedreich ataxia: four year follow up. Arch. Neurol. 62(4), 621–626 (2005).
- 83 The Friedreich's Ataxia Treatment Pipeline is a visual tool for communicating the progress of research and development on lead therapeutic candidates. www.curefa.org/pipeline.